Welcome to our dedicated page for Interpace Biosciences SEC filings (Ticker: IDXG), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Interpace Biosciences, Inc. (IDXG) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. These documents give detailed insight into Interpace’s molecular diagnostics business, its thyroid-focused testing franchise, and its financial condition.
Through periodic reports such as Annual Reports on Form 10-K and Quarterly Reports on Form 10-Q, Interpace discusses revenue from its clinical services, test volumes, gross profit, operating income or loss, cash flows, and non-GAAP measures like Adjusted EBITDA, which it defines in the filings. These reports also include risk factor discussions related to reimbursement for its tests, dependence on clinical services, financing needs, and the impact of coverage decisions on products such as PancraGEN.
Current Reports on Form 8-K document material events, including the announcement that Interpace fully repaid its outstanding term loan facility with BroadOak Capital Partners before maturity and the release of quarterly financial results. These filings often incorporate press releases by reference, providing the full text of the company’s operational and financial updates.
Investors can also review proxy materials and other governance-related filings, where applicable, to understand executive and board matters, and registration statements if the company undertakes capital-raising or other securities transactions. For those tracking potential insider activity, Forms 3, 4, and 5 (when filed) present information on beneficial ownership and changes in holdings by officers, directors, and significant shareholders.
On Stock Titan, these SEC filings are updated as new documents are posted to EDGAR. AI-powered tools summarize key points from lengthy forms such as 10-K and 10-Q, helping readers quickly identify disclosures on reimbursement risk, test portfolio changes, balance sheet developments, and non-GAAP reconciliations. Users can move from high-level AI summaries into the full-text filings to examine Interpace’s reported results and risk factors in greater detail.
1315 Capital II, L.P. reported acquisition or exercise transactions in a Form 4 filing for IDXG. The filing lists transactions totaling 9,424,941 shares at a weighted average price of $2.02 per share. Following the reported transactions, holdings were 9,405,941 shares.
Ampersand 2018 Limited Partnership, a 10% owner of Interpace Biosciences, Inc., reported converting preferred stock into common shares. On January 20, 2026, it converted 28,000 Series C Convertible Preferred shares into 13,861,386 shares of common stock.
The preferred shares had a stated value of $1,000 per share and a conversion price of $2.02 per common share, which determines how many common shares are issued on conversion. Following this transaction, the reporting holder owned 13,861,386 common shares directly and no remaining Series C preferred shares.
Interpace Biosciences, Inc. filed a current report describing preliminary, unaudited revenue for the year ended December 31, 2025, as outlined in a related press release.
The company also reported that all outstanding shares of its Series C Preferred Stock were converted into shares of its common stock, simplifying its equity structure. The press release dated January 20, 2026 is furnished as an exhibit to the report and is not treated as filed for purposes of liability under the Exchange Act.
Interpace Biosciences, Inc. reported that on December 3, 2025 it fully repaid its outstanding term loan facility with BroadOak Capital Partners before the loan’s scheduled maturity. This means the company has cleared that specific debt obligation earlier than required, which can simplify its capital structure and reduce future interest payments. The update was shared through a press release attached as an exhibit, providing more detail on the repayment and its context for the business.
Interpace Biosciences, Inc. (IDXG) furnished an 8-K under Item 2.02 announcing results of operations and financial condition for the quarter ended September 30, 2025. The company issued a press release, included as Exhibit 99.1, providing the full details.
The information in Item 2.02, including Exhibit 99.1, is being furnished and is not deemed “filed” for purposes of Section 18 of the Exchange Act. The filing also lists the Cover Page Interactive Data File as Exhibit 104.
Interpace Biosciences (IDXG) reported Q3 results. Revenue was $8.756 million, down 29% from $12.295 million a year ago, reflecting the April 2025 loss of Medicare coverage for PancraGEN. Gross profit was $5.439 million. Operating income from continuing operations was $1.145 million versus $2.301 million, and net income was $0.911 million versus $1.676 million.
For the nine months, revenue was $29.504 million, down from $34.515 million; operating income was $2.507 million versus $6.047 million; net income was $1.918 million versus $4.821 million. The company recorded $0.7 million in severance and related costs tied to its restructuring plan. Cash and cash equivalents were $1.423 million as of September 30, 2025, with current assets of $9.130 million and current liabilities of $5.945 million. The BroadOak term loan balance was $1.0 million (fair value $0.977 million) with the maturity extended to December 31, 2025 and interest-only payments beginning July 1, 2025. Shares outstanding were 4,428,539 as of November 7, 2025.
Adjusted EBITDA was $1.263 million in Q3 and $3.735 million year-to-date. Management notes continued focus on cost controls, receivable collections, and financing or strategic alternatives following the PancraGEN coverage change.